Table 6 Diagnostic Characteristics of Functional Testing, Semi-Quantitative Coronary Artery Calcification Assessment, and Primary Prevention Guidelines in the Subgroup of Patients Referred for Functional Testing For Asymptomatic Coronary Artery Disease Screening
Asymptomatic Cohort (n = 77) | MACE | No MACE | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | PLR (95% CI) | NLR (95% CI) |
|---|---|---|---|---|---|---|---|---|
Functional Study |  |  | 6.3% (0.2%—30.2%) | 96.7% (88.7%—99.6%) | 33.3% (4.6%—83.8%) | 79.7% (77.5%—81.8%) | 1.91 (0.18 – 19.72) | 0.97 (0.85 – 1.11) |
 Abnormal | 1 | 2 | ||||||
 Normal | 15 | 59 | ||||||
Coronary Artery Calcifications (CAC) |  |  | 37.5% (15.2%—64.6%) | 75.4% (62.7%—85.5%) | 28.8% (15.6%—46.4%) | 82.1% (75.4%—87.3%) | 1.52 (0.71 – 3.29) | 0.83 (0.55 – 1.24) |
 Present | 6 | 15 | ||||||
 Absent | 10 | 46 | ||||||
Moderate or Severe CAC |  |  | 6.3% (0.2%—30.2%) | 95.1% (86.3%—99.0%) | 25.0% (3.6%—75.0%) | 79.5% (77.1%—81.6%) | 1.27 (0.14 – 11.41) | 0.99 (0.86 – 1.13) |
 Present | 1 | 3 | ||||||
 Absent | 15 | 58 | ||||||
2019 ACC/AHA Guidelinea |  |  | 12.5% (1.6%—38.4%) | 95.0% (86.1%—99.0%) | 40.0% (10.8%—78.5%) | 80.3% (77.0%—83.2%) | 2.50 (0.46 – 13.7) | 0.92 (0.76 – 1.12) |
 Recommend statin therapy discussion | 2 | 3 | ||||||
 Do not recommend statin therapy discussion | 14 | 57 |